Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States

JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of an authorized generic of Cubicin®1 (daptomycin for injection) 500 mg per vial in the United States. Daptomycin... Biopharmaceuticals, Generics, Product Launch Teva Pharmaceutical, Cubicin, daptomycin, Merck
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news